Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS007 in advanced solid tumors
NCT05049265Phase 1Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JS007 in solid tumor (advanced stage), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Maximum Tolerated Dose up to 12 months, Dose Limiting Toxicity at 21 days and 3 more. Status: unknown.
02
Drugs
JS007
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05049265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049265.